Royal College of Surgeons in Ireland

Amy Short

Marie Eugenie Migaud

Tracy Robson

Helen McCarthy

Adrien Kissenpfennig

Anita Yakkundi

David Grieve

Rachel Bennett

Helen Mccarthy

The inventors have determined that increasing the expression level or activity of FKBP-L polypeptide in a subject, which can be provided by expression of nucleic acids encoding FKBP-L or by providing FKBP-L polypeptides to a subject is advantageous for use in the treatment of obesity and obesity-related disorders. In particular increased expression or activity of FKBP-L polypeptide in a subject may be used to treat excessive weight gain (which can be characterised as obesity), glucose intolerance, diabetes and metabolic syndrome, which are closely linked to obesity and insulin resistance. FKBP-L can also be used as a biomarker for obesity and obesity-related disorders.

Use of FKBP-L polypeptides and nucleic acids for the treatment of obesity

Growing community of inventors

Magerafelt Londonderry, United Kingdom

Amy Short